Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Protocol Number: HJKC3-0003. Treatment Free Remission After Asciminib Based Therapy in Chronic Phase Chronic Myeloid Leukemia (CP-CML) Patients Who Relapsed After a Prior Attempt at TKI Discontinuation

NCT04838041 is registered in ClinicalTrials.gov with Medical College of Wisconsin as lead sponsor.

NCT NCT04838041
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04838041 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Protocol Number: HJKC3-0003. Treatment Free Remission After Asciminib Based Therapy in Chronic Phase Chronic Myeloid Leukemia (CP-CML) Patients Who Relapsed After a Prior Attempt at TKI Discontinuation
Lead sponsor
Medical College of Wisconsin
Phase
Phase 2
Overall status
Recruiting
Start date
November 11, 2021
Completion date
July 31, 2029
Enrollment
51 (estimated)
Sites
5

Conditions

As the registry lists them; a condition with its own page is linked.

chronic phase chronic myelogenous leukemia